Search Results - "Jablons, David M."

Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC) by Hsu, Ping-Chih, Jablons, David M, Yang, Cheng-Ta, You, Liang

“…The epidermal growth factor receptor (EGFR) pathway is a well-studied oncogenic pathway in human non-small cell lung cancer (NSCLC). A subset of advanced NSCLC…”
Get full text

A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression by Okada, Nobuhiro, Lin, Chao-Po, Ribeiro, Marcelo C, Biton, Anne, Lai, Gregory, He, Xingyue, Bu, Pengcheng, Vogel, Hannes, Jablons, David M, Keller, Andreas C, Wilkinson, J Erby, He, Biao, Speed, Terry P, He, Lin

“…As bona fide p53 transcriptional targets, miR-34 microRNAs (miRNAs) exhibit frequent alterations in many human tumor types and elicit multiple p53 downstream…”
Get full text

NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer by Blakely, Collin M., Pazarentzos, Evangelos, Olivas, Victor, Asthana, Saurabh, Yan, Jenny Jiacheng, Tan, Irena, Hrustanovic, Gorjan, Chan, Elton, Lin, Luping, Neel, Dana S., Newton, William, Bobb, Kathryn L., Fouts, Timothy R., Meshulam, Jeffrey, Gubens, Matthew A., Jablons, David M., Johnson, Jeffrey R., Bandyopadhyay, Sourav, Krogan, Nevan J., Bivona, Trever G.

“…Although oncogene-targeted therapy often elicits profound initial tumor responses in patients, responses are generally incomplete because some tumor cells…”
Get full text

The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC) by Hsu, Ping-Chih, Yang, Cheng-Ta, Jablons, David M, You, Liang

“…The advancement of new therapies, including targeted therapies and immunotherapies, has improved the survival of non-small-cell lung cancer (NSCLC) patients in…”
Get full text

Scientific Advances and New Frontiers in Mesothelioma Therapeutics by Mutti, Luciano, Peikert, Tobias, Robinson, Bruce W S, Scherpereel, Arnaud, Tsao, Anne S, de Perrot, Marc, Woodard, Gavitt A, Jablons, David M, Wiens, Jacinta, Hirsch, Fred R, Yang, Haining, Carbone, Michele, Thomas, Anish, Hassan, Raffit

“…Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that arises from the mesothelial surface of the pleural and peritoneal cavities, the…”
Get more information

A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies by Kratz, Johannes R, MD, He, Jianxing, Prof, Van Den Eeden, Stephen K, PhD, Zhu, Zhi-Hua, Prof, Gao, Wen, Prof, Pham, Patrick T, BS, Mulvihill, Michael S, BS, Ziaei, Fatemeh, BS, Zhang, Huanrong, MD, Su, Bo, MD, Zhi, Xiuyi, Prof, Quesenberry, Charles P, PhD, Habel, Laurel A, BS, Deng, Qiuhua, BS, Wang, Zongfei, BS, Zhou, Jiangfen, BS, Li, Huiling, PhD, Huang, Mei-Chun, PhD, Yeh, Che-Chung, PhD, Segal, Mark R, Prof, Ray, M Roshni, BS, Jones, Kirk D, Prof, Raz, Dan J, MD, Xu, Zhidong, MD, Jahan, Thierry M, MD, Berryman, David, PharmD, He, Biao, PhD, Mann, Michael J, Dr, Jablons, David M, Prof

“…Summary Background The frequent recurrence of early-stage non-small-cell lung cancer (NSCLC) is generally attributable to metastatic disease undetected at…”
Get full text

Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells by You, Bin, Yang, Yi-Lin, Xu, Zhidong, Dai, Yuyuan, Liu, Shu, Mao, Jian-Hua, Tetsu, Osamu, Li, Hui, Jablons, David M, You, Liang

“…Alterations of the EGFR/ERK and Hippo/YAP pathway have been found in non-small cell lung cancer (NSCLC). Herein, we show that ERK1 and ERK2 have an effect on…”
Get full text

Nasopharyngeal carcinoma-Review of the molecular mechanisms of tumorigenesis by Chou, Josephine, Lin, Yu-Ching, Kim, Jae, You, Liang, Xu, Zhidong, He, Biao, Jablons, David M.

“…Nasopharyngeal carcinoma (NPC) is a head and neck cancer rare throughout most of the world but common in certain geographic areas, such as southern Asia. While…”
Get full text

Targeting YAP in malignant pleural mesothelioma by Zhang, Wen‐Qian, Dai, Yu‐Yuan, Hsu, Ping‐Chih, Wang, Hui, Cheng, Li, Yang, Yi‐Lin, Wang, Yu‐Cheng, Xu, Zhi‐Dong, Liu, Shu, Chan, Geraldine, Hu, Bin, Li, Hui, Jablons, David M., You, Liang

“…Malignant mesothelioma is an aggressive cancer that is resistant to current therapy. The poor prognosis of mesothelioma has been associated with elevated…”
Get full text

Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma by Capelletti, Marzia, Dodge, Michael E, Ercan, Dalia, Hammerman, Peter S, Park, Seung-Il, Kim, Jhingook, Sasaki, Hidefumi, Jablons, David M, Lipson, Doron, Young, Lauren, Stephens, Phil J, Miller, Vincent A, Lindeman, Neal I, Munir, Kiara J, Richards, William G, Jänne, Pasi A

“…Targetable oncogenic alterations are detected more commonly in patients with non-small cell lung cancer (NSCLC) who never smoked cigarettes. For such patients,…”
Get full text

Inhibition of yes‐associated protein down‐regulates PD‐L1 (CD274) expression in human malignant pleural mesothelioma by Hsu, Ping‐Chih, Miao, Jinbai, Wang, Yu‐Cheng, Zhang, Wen‐Qian, Yang, Yi‐Lin, Wang, Chih‐Wei, Yang, Cheng‐Ta, Huang, Zhen, You, Joanna, Xu, Zhidong, Jablons, David M., You, Liang

“…Although tumour PD‐L1 (CD274) expression had been used as a predictive biomarker in checkpoint immunotherapy targeting the PD1/PD‐L1 axis in various cancers,…”
Get full text

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer by JOHNSON, David H, FEHRENBACHER, Louis, HOLMGREN, Eric, KABBINAVAR, Fairooz, NOVOTNY, William F, HERBST, Roy S, NEMUNAITIS, John J, JABLON, David M, LANGER, Corey J, DEVORE, Russell F, GAUDREAULT, Jacques, DAMICO, Lisa A

“…To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. In a…”
Get full text

Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion by Dresler, Carolyn M, Olak, Jemi, Herndon, 2nd, James E, Richards, William G, Scalzetti, Ernest, Fleishman, Stewart B, Kernstine, Kemp H, Demmy, Todd, Jablons, David M, Kohman, Leslie, Daniel, Thomas M, Haasler, George B, Sugarbaker, David J

“…To demonstrate the efficacy, safety, and appropriate mode of instillation of talc for sclerosis in treatment of malignant pleural effusions (MPEs). A…”
Get more information

Genetic and immunologic features of recurrent stage I lung adenocarcinoma by Kratz, Johannes R., Li, Jack Z., Tsui, Jessica, Lee, Jen C., Ding, Vivianne W., Rao, Arjun A., Mann, Michael J., Chan, Vincent, Combes, Alexis J., Krummel, Matthew F., Jablons, David M.

“…Although surgery for early-stage lung cancer offers the best chance of cure, recurrence still occurs between 30 and 50% of the time. Why patients frequently…”
Get full text

Inhibition of CK2α down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells by Zhang, Shulin, Wang, Yucheng, Mao, Jian-Hua, Hsieh, David, Kim, Il-Jin, Hu, Li-Min, Xu, Zhidong, Long, Hao, Jablons, David M, You, Liang

“…Protein kinase CK2 is frequently elevated in a variety of human cancers. The Hedgehog (Hh) signaling pathway has been implicated in stem cell maintenance, and…”
Get full text

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer by Zhou, Bin-Bing S., Peyton, Michael, He, Biao, Liu, Changnian, Girard, Luc, Caudler, Eian, Lo, Yvonne, Baribaud, Frederic, Mikami, Iwao, Reguart, Noemi, Yang, Gengjie, Li, Yanlong, Yao, Wenqing, Vaddi, Kris, Gazdar, Adi F., Friedman, Steven M., Jablons, David M., Newton, Robert C., Fridman, Jordan S., Minna, John D., Scherle, Peggy A.

“…We describe here the existence of a heregulin-HER3 autocrine loop, and the contribution of heregulin-dependent, HER2-mediated HER3 activation to gefitinib…”
Get full text

Inhibition of yes‐associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model by Hsu, Ping‐Chih, Miao, Jinbai, Huang, Zhen, Yang, Yi‐Lin, Xu, Zhidong, You, Joanna, Dai, Yuyuan, Yeh, Che‐Chung, Chan, Geraldine, Liu, Shu, Urisman, Anatoly, Yang, Cheng‐Ta, Jablons, David M., You, Liang

“…Yes‐associated protein (YAP) is a main mediator of the Hippo pathway and promotes cancer development and progression in human lung cancer. We sought to…”
Get full text

Systematic comparison of two whole-genome amplification methods for targeted next-generation sequencing using frozen and FFPE normal and cancer tissues by Mendez, Pedro, Fang, Li Tai, Jablons, David M., Kim, Il-Jin

“…Sequencing key cancer-driver genes using formalin-fixed, paraffin-embedded (FFPE) cancer tissues is becoming the standard for identifying the best treatment…”
Get full text

SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer by Lui, Natalie S, Yang, Yi-Wei, van Zante, Annemieke, Buchanan, Petra, Jablons, David M, Lemjabbar-Alaoui, Hassan

“…Lung cancer is one of the most deadly cancers; median survival from diagnosis is less than one year in those with advanced disease. Novel lung cancer…”
Get full text

Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer by MAZIERES, Julien, BIAO HE, LIANG YOU, ZHIDONG XU, LEE, Amie Y, MIKAMI, Iwao, REGUART, Noemi, ROSELL, Rafael, MCCORMICK, Frank, JABLONS, David M

“…Aberrant activation of the Wingless-type (Wnt) signaling pathway is associated with a variety of human cancers, and we recently reported the importance of…”
Get full text